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Purpose: The treatment of fractures involves addressing the biology of fracture repair and the mechanical
stability of fracture fixation. Traditionally it has included the addition of bone graft to enhance healing.
New advances in the understanding of the cellular and molecular mechanisms of fracture repair have led
to the use of growth factors to accelerate bone healing. This study aimed to assess the advantages of
autologous stem cell use for atrophic mandibular fracture treatment in comparison to standard
technique.
Materials and methods: A total of 35 patients (14 male and 21 female) were treated for fractures of
atrophic mandibles between January 2011 and December 2014. Surgical technique provided mini-
invasive open reduction with or without immediate homologous bone graft, while selected patients
received autologous bone marrow aspirate cell grafts in addition to the standard treatment. Demographic
data and details of treatment and outcomes were recorded.
Results: Patients were categorized according to the use of autologous stem cells, leaving 17 patients
treated with standard technique and autologous stem cells (Group A) and 18 treated with standard
osteosynthesis only (Group B). Of the 35 patients, 26 had bilateral fractures; most patients had significant
medical co-morbidities. Immediate bone graft was used in 37.1% of patients (7 in group A and 6 in group
B). Complications occurred in 5 patients (14.3%). Two patients in group B (11.1%) showed non-union of
the fracture. One patient in group A (5.8%) and one patient in group B (5.5%) showed wound dehiscence
and were treated conservatively; one patient in group B had a local infection (5.5%), one out of 35 (2.8%),
that was managed by prolonged antibiotic treatment.
Conclusions: Despite the advanced age and medical co-morbidities of the vast majority of patients, mini-
invasive open approach with autologous bone graft ensures a fast and excellent recovery. Moreover, the
management of atrophic mandibular fractures by bone marrow aspirate cells is a safe and useful pro-
cedure which has a lower complication rate when compared to standard technique.
© 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights
reserved.
1. Introduction
Atrophy can be considered the end stage of edentulism; it leads
to a decrease in bone mandibular mass, thus making it more
vulnerable to fracture. In 1996, mandibular atrophy was classified
by Luhr et al. (1996) into three categories based on mandibular
height: Class I, 16e20 mm; Class II, 11e15 mm; and Class III,
<10mm. Today, about the 10% of population of developed countries
is completely edentulous. Despite the total tooth loss process, the
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rate has fallen over the last decades, thanks to medical progress;
however, it is estimated that percentage of edentulous individuals
over age 65 years will remain constant in the future, because of the
increasing elderly population. Edentulism is more prevalent in
persons with less than a high school education, those without
dental care history, heavy smokers and alcohol abusers. The per-
centage of edentulous population varies by countries; today,
approximately 8% of the adults in the United States are completely
edentulous (Beltr!an-Aguilar et al., 2007). The percentage ranges
between 8% and 15% in Europe, with a value of about 10.5% in Italy,
together with a consistent difference between the northern and
southern regions of the country. In Italy, about 22.6% of people
between 65 and 69 years of age are edentulous; the percentage
rises to 34.8% between 70 and 74 years of age, is almost doubled
between 75 and 79 years, and reaches 60% in people more than 80
years of age.
Because fractures of the edentulous mandible are relatively
uncommon, most practitioners have limited experience in treating
patients with this problem. Treatment of fractures in older patients
with bone atrophy is characterized by high morbidity due to local
and general factors (Ellis and Price, 2008). In fact, serious compli-
cations are common, especially in patients with atrophy classes II
and III, such as non-union or fracture of hardware, the incidence of
which has been reported to range between 4% and 20% (Luhr et al.,
1996; Bruce and Strachan, 1976; Buchbinder, 1993; Eyrich et al.,
1997; Iatrou et al., 1998; Kunz et al., 2001) and is probably linked
to the bone height in the area of fractures (Bruce and Ellis, 1993;
Wittwer et al., 2006).
Another issue related to atrophic mandibular fractures is the co-
morbidities that are often exhibited by aged patients, which can
increase the risk of general anesthesia (Yamamoto et al., 2011;
Clayman and Rossi, 2012). In addition, the physiologically
decreased osteogenesis process, together with local factors relating
to atrophic cortical bone and inadequate blood supply, contribute to
make this surgery challenging to physicians (Wongchuensoontorn
et al., 2009).
The basic principles of atrophic mandible fracture management
include open reduction and internal fixation to achieve restoration
in terms of aesthetics and functionality. The surgical technique has
evolved through decades, passing from the use of intraosseous
wires to fix fractures in the 1970s (Bruce and Strachan, 1976), by the
introduction of internal fixation method by osteosynthesis plates
and screws in the 1990s, together with the first report discouraging
the clinical and biological value of bone grafting in older patients
because of their high number of co-morbidities (Bruce and Ellis,
1993). However, in 2008, Ellis and Price (2008) showed that atro-
phic mandibular fractures treated by open reduction, internal plate
fixation and immediate bone grafts had an extremely high rate of
success. Although they encountered no problems from taking
autogenous grafts in their patients, harvesting a bone graft from an
elderly patient could be problematic. Autografts can come from a
variety of areas. The iliac crest is by the far the most common
source, due to the rich presence of progenitor cells and growth
factors, limited donor site morbidity, fair bone quantity and relative
ease of harvest. It would therefore be preferable to provide osteo-
genic potential in a less invasive manner. Recently, the concept of
tissue engineering and regenerative medicine has been widely
accepted in medicine (Langer and Vacanti, 1993), and several clin-
ical studies have been performed in the field of oral and maxillo-
facial surgery, especially concerning oral rehabilitation, including
studies of bone and periodontal regenerative medicine. In fact, the
vast majority of articles published recently in the literature have
focused on the use of autologous stem cells in atrophic mandibles
to induce and enhance new bone formation to allow implant
placement. For instance, Rickert et al. (2011), Katagiri et al. (2016),
Kawai et al. (2015), and Yamada et al. (2013) have observed and
documented the safe use of mesenchymal stem cell (MSC) bone
marrow (BM)-derived bone augmentation for dental implants in
patients affected by severe alveolar bone atrophy. All of these au-
thors indicated that this minimally invasive bone regeneration
technique was a useful and novel option in dental implant treat-
ment of severe bone atrophy, showing good results through MSCs'
great osteogenic potential, together with poor donor site morbidity
and few inflammatory signs. In support of these statements, other
reports of animal models have presented encouraging results.
Osugi et al. (2012) have shown how MSCs enhance migration,
proliferation and osteogenic marker expression in a rat calvarian
bone defect model, and this was confirmed by Inukai et al. (2013) a
fewmonths later. An interesting article stating the capacity of MSCs
to regulate the turnover of local bone by a paracrine effect, already
mentioned by Herford and Boyne (2008) , was reported in a rat
bisphosphonate-related osteonecrosis of the jaw-like model by
Ogata et al., 2015 , for which histological analysis confirmed the
presence of osteoclasts in the MSC group.
However, clinical use of stem cells requires highly qualified
safety investigation and quality management of cell handling, and
it is very expensive. These limitations currently impede the wide-
spread use of stem cells for alveolar bone regeneration therapy;
moreover, it has been shown that the implanted cells do not survive
long (Muller-Ehmsen et al., 2002; Toma et al., 2009; Ide et al., 2010).
It is known that osteoblasts develop from the proliferation and
differentiation of osteoprogenitor cells and that these progenitors
arise from a bone marrow (BM) population called mesenchymal
stem cells (MSCs). MSCs have the ability to self-renewand present a
multilineage potential (Kan et al., 2005). Their plasticity makes
them a promising resource for research in cellular therapy of tissue
defects, and several authors have demonstrated how autologous
stem cells aspirated from BM can enhance bone healing in in vitro
and in vivo studies (Kan et al., 2005; Rickert et al., 2011; Watson
et al., 2014; Katagiri et al., 2013; Osugi et al., 2012; Inukai et al.,
2013; Kawai et al., 2015; Katagiri et al., 2016). In this regard,
osteoinductive growth factors such as bone morphogenic protein
(BMP)-2 have been already used with osteoconductive materials to
promote bone regeneration (Herford and Boyne, 2008). For
example, platelet-rich plasma (PRP), collected by centrifugation of
autologous peripheral blood, has been reported to enhance bone
regeneration or to promote soft and hard tissue healing (Yamada
et al., 2013). PRP includes growth factors such as platelet-derived
growth factor (PDGF), transforming growth factor-b (TGF-b),
vascular endothelial growth factor (VEGF) and epithelial growth
factor (EGF) (Marx et al., 1988). PRP also has several advantages
over the use of animal sera or recombinant factors from potentially
safe and effective clinical applications (Prins et al., 2009).
In this scenario, we present our view of atrophic mandibular
fracture management, by presenting a consistent single surgeon
case series. We review this series to confirm the usefulness of a
minimally invasive surgical approach to the treatment of this type
of fracture, and to assess the great regenerative potential of autol-
ogous stem cells grafted from the anterior iliac bone to facilitate
bone healing and as well as recovery in patients with mandibular
moderate-to-severe atrophy. Our data respect the epidemiology of
this pathology, which is linked to the fact that our geographic area,
Tuscany, represents the region with one of the highest concentra-
tion of senior citizens in Italy, with a global percentage of adults
more than 65 years old of 23.2%, against a national value of 20.2%;
most of them are females (58%), and 62% are over 75 years, in
comparison to a national rate of women over 75 of 52%. Therefore,
our tertiary care hospital represents the reference center for this
type of uncommon fractures, justified by the presence of a large
number of elderly patients.
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2. Materials and methods
2.1. Study population
This prospective study included 35 patients treated by open
reduction, with or without osteogenic BMAC use, of fractures of
completely edentulous atrophic mandibles (!15 mm bone height
in the area of fracture) at theMaxillo-Facial Surgery Unit of Florence
between January 2011 and December 2014. Only patients over 65
years of age were enrolled in our study, because it represents the
elderly population, who are the main individuals affected by severe
mandible atrophy, the challenging management of which is influ-
enced by a high prevalence of co-morbidities in comparison to
those in younger patients. On the other hand, fractures of atrophic
mandible class I were excluded because we wanted to focus our
attention on the most difficult cases only, considering that serious
complications are commonly reported for class II and III in up to
20% of cases. Moreover, patients not meeting these inclusion terms,
patients presenting with pathological fractures, patients who did
not give their own consent to be enrolled in this study protocol,
patients with a previous medical history of mandible fractures,
patients who had undergone head and neck radiotherapy treat-
ment, and patients with insufficient preoperative or postoperative
data were excluded from our analysis. Patients were given exten-
sive information about the procedures, including the surgery, graft
material, plates, and screws and the uncertainties of using a new
bone-regenerative method.
The research protocol was approved by the Institute's and Uni-
versity Ethics Committee on human research and was conducted in
accordancewith all accepted standards for human clinical research.
All patients who accepted enrollment in this study gave their
informed consent.
The following information was collected from the patients'
medical records: age and sex, concomitant systemic medical con-
ditions, cause and site(s) of fracture(s), height of bone in the area of
fracture(s), displacement of fracture(s), surgical details, adequacy of
reduction, postoperative pain and diffuse local hematoma, hospital
length of stay, long-term complications and duration of follow-up.
A preoperative panoramic radiograph was used to evaluate the
height of bone in the area of fracture, the value of which is always
given to us by radiologists. The amount of displacement of each
fracture was grossly graded by us from mild to severe, where mild
displacement represented a fracture with a slight separation or
angulation of segments, moderate displacement showed the pres-
ence of a significant displacement of fragments, and severe
displacement showed that mandibular segments were not all
aligned with one another with gross override (Ellis and Price, 2008)
(Fig. 1).
To better assess the surgical advantages of our approach and to
compare the incidence of postoperative complications, patients
were prospectively randomly categorized into two treatment
groups. Group A was treated with a more conservative approach,
based on small skin incisions less than 4.5 cm in length, with the
use of standard osteosynthesis plates and screws of 2.0mm, even in
case of comminuted and displaced fractures, plus the addition of
autologous Bone Marrow Aspirate Concentrates (BMACs). Group B
was treated with a more aggressive surgical approach, with
extended mandibular bone exposure together the use of large
reconstructive osteosynthesis plates in case of severe comminuted
and displaced mandibular fractures.
In both groups, bone grafts were used in all cases of commi-
nuted and displaced fractures. Reconstructive osteosynthesis plates
were avoided for patients in group A, and BMACs were used only in
group A. Fig. 2 provides a patient flow chart.
2.2. Surgical technique
Surgery was performed within a maximum of 6 days from the
trauma in all patients. All surgical procedures were performed by
the senior surgeon (G.S.).
Surgical details tabulated included a surgical approach (mini-
mally invasive versus aggressive), presence of comminution or
defect (yes or no), method of reduction of fragments (forceps, bone
clamps, bone plates, wires), simultaneous bone grafting (yes or no),
use of drains (yes or no), surgical procedure length, and intra-
operative complications. The reductionwas judged to be good if the
postoperative radiograph showed a continuous alignments of
fragments, and was considered to be poor if the radiograph showed
a discontinuity in alignment, such as a break of flaring of a ramus on
the posteroanterior radiograph.
Group A provided the following surgical procedures: 2.0-mm
titanium locking “reconstruction” plates with a minimum of 3
screws on each side of the fracture in all cases. A minimally invasive
skin incision approach was used in all cases, with an open access
less than 4.5 cm length (Fig. 3aee). This aimed to achieve the lowest
mandibular bone exposure, in order to reduce possible late com-
plications such as wound dehiscence, local infection, and plate
extrusion.
Group B received large reconstructive osteosynthesis plates
with screws 2.3 mm in case of severe comminuted and displaced
mandibular fractures, with a large skin access (Fig. 4). All other
cases provided screws 2.0 mm but still through a skin access larger
than 4.5 cm in length.
Osteosynthesis plates were always placed extra-periosteally in
both groups, and allo-bone bank grafts were used in all cases of
comminuted and displaced fractures.
Suction and/or Penrose drains were used in 7 patients, all of
whom had bone grafts placed at the time of surgery. The drains
were placed below the platysma muscle and were removed on
either the next day (n¼ 5) or day after that (n¼ 2). None of selected
patients received autologous bone grafts, in order to achieve the
lowest incidence of surgical morbidity in such challenging and
already debilitated patients.
2.3. Bone marrow cell preparation
To harvest the bone marrow cells, the iliac crest bone was
punctured with a bone marrow biopsy needle (Bone Marrow
Aspiration Pack, Harvest Technologies Corporation, Plymouth, MA,
USA) (Fig. 5). A 32-ml quantity of bone marrow was collected and
the aspirate was then transferred quickly into 4 RegenTHT tubes
(RengenKit Extracell BMC:Ref:R-EXB/T//Ref:R-EXB/T2). Each sy-
ringe containing themedullary blood was connected to the transfer
device and put it on the stopper of RegenTHT by carefully applying a
light pressure; in this way the blood was drawn up directly by the
tube (final volume about 5e8 ml). Then a self-adhesive disc was
Fig. 1. Radiograph representing a displaced bilateral body mandibular fracture.
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Fig. 2. Flow chart of patients recruited for the study and different surgical treatment protocols.
Fig. 3. Minimally invasive surgical approach provided by group A protocol: a) minimally invasive bilateral open access with skin incision length of less than 4.5 mm on right side; b)
use of plates and screws 2.0; c) and on left side; d) intraoperative final results; e) postoperative radiograph showing plates and screws 2.0 used for fracture reduction.
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applied to seal the hole in the protective film covering the tube, and
the tube was inverted gently to obtain homogeneous diffusion of
the anti-coagulant.
Bone marrow cells were isolated using the Bone Marrow Aspi-
rate Concentrate (BMAC) system (Bone Marrow Procedure Pack,
Harvest Technologies Corporation, Plymouth, MA, USA) according
to the manufacturer's instructions. The system can use up to two
disposable containers with two chambers. The first chamber con-
tains a floating shelf of a specific density by which the red blood
cells are separated from the nucleated cells, platelets and plasma
during the initial centrifugation phase. Cellular elements and
plasma are automatically transferred into the second chamber and
concentrated by centrifugation. A portion of the supernatant
plasma is removed and the cellular elements are resuspended in
the remaining plasma. The concentration process was evaluated by
Haemocytometry (Sysmex Analyzer, SYSMEX EUROPE GMBH,
Norderstedt, Germany). Tubes were centrifuged for 8 min with a
force of 1600 g (according to the centrifuge manufacturer's in-
structions). Renege THT tubes were inverted gently several times
(at least 20#) to resuspend the cellular elements into the plasma.
Finally, the medullary plasma was withdrawn by using a sterile
syringe equipped with a transfer device (see RengenKit Extracell in
Fig. 6).
Preoperative hematological assessments included a complete
blood count (CBC) with platelet levels. Platelet-rich plasma (PRP)
was isolated in a 200-ml collection bag containing the anti-coag-
ulant citrate under sterilized conditions. Briefly, the blood was
centrifuged for 10 min at 1500 rpm. Yellow plasma (containing the
buffy coat, which included platelets and leukocytes) was obtained
and a second centrifugation at 3500 rpm for 5 min was performed;
then the plasma supernatant was removed. The resulting pellet of
platelets, the buffy coat/plasma fraction (PRP), was resuspended in
the residual 20 ml of plasma and used in the platelet gel. The PRP
Fig. 4. Aggressive surgical approach in accordance with group B protocol: bilateral
body displaced fracture treated by large reconstructive osteosynthesis plate and 2.3
screws through large extra-oral access.
Fig. 5. Bone marrow biopsy puncture in sterile condition.
Fig. 6. RengenKit Extracell BMC:Ref:R-EXB/T//Ref:R-EXB/T2.
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platelet count was 994,000. The values confirmed the platelet
sequestration ability of the process, which showed that the con-
centration was 450% above the baseline platelet count.
Human thrombin in powdered form (5000 units) was dissolved
in 5 ml of 10% calcium chloride in a separate sterile cup.
Finally, PRP, BMACs, and air were aspirated into a sterile syringe.
In another syringe, the thrombin/calcium chloride mixture was
aspirated. The cells were resuspended directly into the PRP. The two
syringes were connected with a T connector, and the plungers of the
syringes were alternatively pushed and pulled. The mixing contents
(tissue engineered bone, TEB) assumed a gel-like consistency
(Fig. 7a) as the thrombin affected the polymerization of the fibrin.
The TEB plus PRP was placed under the periosteum once the
osteosynthesis plateswere positioned and fixed, in order to enhance
tissue healing (Fig. 7b).
2.4. Postoperative follow-up
Recovery time and hospital length of stay were counted, together
with the clinical evaluation of postoperative pain by a visual
analogue scale (VAS), where a score between 2 and 4 identifiedmild
pain, between 5 and 7 moderate pain, over 7 severe pain (Fig. 8).
Postoperative hematoma was evaluated, but only diffused extended
cervical hematoma was considered during the immediate post-
operative follow-up, to identify the onset of dysphagia, dyspnea or
any other compressive symptoms. This was because, first, the vast
majority of our patients were on anti-coagulant medications with a
consequent higher risk for bleeding and postoperative hematoma
appearance; and second, we were comparing patients affected by
the same pathology but treated differently, one group by a more
aggressive surgical protocol that might have caused some of the
above complications. Clinical evaluation was scheduled at 1 week
and at 1, 2, 3, 6 and 12 months after surgery, then annually. Physical
assessment together with photographic records and radiographic
analysis were routinely performed, and the incidence of any com-
plications such as infection, dehiscence, BMAC donor site problems,
loosening and/or fractures of screws/plates were recorded.
Orthopantomography was performed every scheduled visit, and
computed tomography (CT) scans were performed at 6 and 12
months after surgery. Radiological investigations were used to
assess the quality of surgical reduction, to evaluate bone consoli-
dation and to detect any postoperative complications. Their results
were registered in a specific form.
2.5. Statistical analysis
Continuous data descriptive statistics were performed, 95%
confidence interval (CI) of the mean and standard deviation were
calculated. A t-test was used, and p < 0.05 was considered statis-
tically significant. Fisher and chi-square tests to analyze a 2 # 2
contingency table were used for categorical data.
3. Results
3.1. Study population
Clinical characteristics are summarized in Tables 1 and 2,
including groups A and B data, respectively. Patients' age was
almost equivalent among the two groups, in which group A pre-
sented with a median age of 77 years (mean 75.47 ± SD 5.23, 95% CI
72.78e78.16, range 66e85) versus group B, whose median age was
76.5 years (mean 75.44 ± SD 5.07, 95% CI 72.92e77.96, range
66e83) (p ¼ 0.9881). Of the patients, 31.4% were male, while 68.9%
were female, with a median age of 74 years (mean 72.82 ± SD 5.47,
95% CI 69.14e76.50, range 66e85) and 78 years (mean 76.67 ± SD
4.49, 95% CI 74.77e78.56, range 67e83).
The vast majority of patients presented with at least one sys-
temic illness that had to be managed in association with their
fractures. The most common co-morbidities were hypertension
(n¼ 8, 25.7%), chronic obstructive pulmonary disease (n¼ 6, 17.1%),
osteoporosis (n ¼ 4, 11.4%), diabetes (n ¼ 2, 5.7%), dementia (n ¼ 2,
5.7%) and previous stroke (n ¼ 2, 5.7%). Only 10 patients had no
associated systemic co-morbidities; four of these were the youn-
gest patients.
Mandibular atrophy class III was documented in five patients in
group A (14.3%) and four patients in group B (11.4%). Causes of
fractures included falls (n ¼ 23, 65.7%), vehicular accidents (n ¼ 10,
28.6%) and assaults (n ¼ 2, 5.7%).
The vast majority of cases reported bilateral mandibular frac-
tures (74.3%), in fact only nine of 35 patients reported a unilateral
fracture (25.7%), with a final total of 61 mandibular fractures to
treat. The nine unilateral fractures were all located in the
Fig. 7. Platelet-rich plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC) aspirate together the thrombin/calcium chloride mixture resuspended directly into the PRP assumed a
gel-like consistency. a) TEB with gel-like consistency; b) TEB positioned sub-periosteally plus PRP dose on osteosynthesis site. TEB ¼ tissue engineered bone.
Fig. 8. Visual analogue scale (VAS) for pain: 1) VAS <2 denotes no pain, 2) VAS 3e4
denotes mild pain, 3) VAS 5e7 denotes moderate pain, and 4) VAS >7 denotes severe
pain.
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mandibular body; about three-fourths of the bilateral fractures
(73.1%) were diagnosed in the body area, while the remaining 28.9%
presented as second site of fracture the contralateral mandibular
angle. Two of the angle fractures were not atrophic (>15 mm in
height) but nonetheless were included in the analysis for
completeness. A total of 18 patients, 11 in group A and 7 in group B,
presented with comminuted and displaced fractures (51.4%),
whereas 24 were bilateral and 6 unilateral fractures, totaling 30
overall (49.2%). Fracture displacement ranged from minimal to se-
vere. Unilateral fractures seemed to be less displaced than bilateral
fractures. The most significant displacement occurred in the bilat-
eral body fracture.
A total of 14 patients needed immediate bone graft (40%); all of
themwere affected by comminuted and displaced fractures. Nine of
14 patients were treated by a minimally invasive external surgical
approach with bone graft plus the use of BMACs (64.3%) without
the use of any reconstructive osteosynthesis plate; the remaining 5
patients underwent operation by a more aggressive surgical
approach, in accordance with protocol B, by a more extended skin
incision, exposing the whole mandibular body, using the bone graft
plus a reconstructive osteosynthesis plate when needed (severe
dislocated fractures). Reconstructive osteosynthesis plates were
avoided in group A, while they were used in three patients in group
B (16.6%); two reported bilateral comminuted and displaced frac-
tures, and the third with unilateral severe displaced fracture. The
overall use of these tools was of 8.6%.
No major intraoperative complications were seen in any pa-
tients. However, 5 of 35 patients presented postoperative compli-
cations (14.3%); a total number of 2 non-union fractures were
recorded (5.7%), all of them encountered in group B (2/18, 11.1%),
both presented as bilateral body fractures treated by bone graft,
plus reconstructive osteosynthesis plate in case of atrophy class III
(1/18, 5.5%). The first case, a man 75 years of age with a mandibular
atrophy class II, underwent a surgical revision of the non-union
fracture; in contrast, a woman 83 years of age, affected by a
mandibular atrophy class III, did not undergo any second surgical
procedure, and during her clinical follow-up her functional out-
comes remained stable without any worsening of the complication
experienced.
A final number of two wound dehiscences were seen (5.7%), one
in group A (1/17, 5.8%) and one in group B (1/18, 5.5%), both in
patients affected by diabetes and over 70 years of age. Both patients
required daily local medications in our clinic for about 3 weeks
since they recovered completely.
Table 1
Characteristics of patients in group A who received BMACs.
Age (y) Sex Co-morbidities Class of atrophy Type of fracture Second site of fracture Comminuted/displaced fracture Bone graft Complications
66 M None II Unilateral e Yes No None
71 M HBP II Bilateral Body region No No None
78 F HBP III Bilateral Body region Yes Yes None
79 F HBP II Bilateral Body region Yes Yes None
68 F None II Bilateral Contralateral angle Yes Yes None
73 F None II Bilateral Body region Yes Yes None
77 F COPD II Bilateral Body region No No None
79 F HBP II Bilateral Contralateral angle No No None
85 M HBP III Bilateral Contralateral angle Yes Yes None
81 F DM III Unilateral e Yes Yes Wound dehiscence
77 F Previous IMA II Unilateral e Yes No None
76 M COPD II Unilateral e No No None
75 M COPD III Bilateral Contralateral angle Yes Yes None
69 F OSP II Bilateral Body region Yes Yes None
70 F None II Bilateral Body region No No None
78 F COPD III Bilateral Body region No No None
81 F Dementia II Bilateral Contralateral angle Yes Yes None
M ¼ male; F ¼ female; DM ¼ mellitus diabetes; HBP ¼ high blood pressure; IMA ¼ ischemic myocardial attack; COPD ¼ chronic obstructive pulmonary disease;
OSP ¼ osteoporosis.
Table 2
Characteristics of patients in group B treated without BMACs.
Age (y) Sex Co-morbidities Class of atrophy Type of fracture Second site of fracture Comminuted/displaced fracture Bone graft Complications
69 M HBP II Unilateral e Yes Yes None
66 M None II Unilateral e No No None
67 F None II Unilateral e Yes No None
75 M Previous IMA II Bilateral Body region Yes Yes Non-union
77 F OSP II Bilateral Body region No No None
79 F COPD II Bilateral Body region No No None
80 F COPD II Bilateral Body region No No None
82 F OSP II Bilateral Body region No No None
83 F Dementia III Bilateral Body region Yes Yes Non-union
69 M None II Bilateral Body region No No None
74 M None II Unilateral e No No None
76 F OSP III Bilateral Contralateral angle Yes Yes None
72 F None II Unilateral e No No None
78 F DM II Bilateral Body region No No Wound dehiscence
75 M HBP II Bilateral Body region Yes No Local infection
77 F HBP III Bilateral Contralateral angle Yes Yes None
80 F OSP III Bilateral Body region No No None
79 F None II Bilateral Body region No No None
M ¼ male; F ¼ female; DM ¼ mellitus diabetes; HBP ¼ high blood pressure; IMA ¼ ischemic myocardial attack; COPD ¼ chronic obstructive pulmonary disease;
OSP ¼ osteoporosis.
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Only one patient experienced local infection (2.8%) in group B
(1/18, 5.5%) and he was operated on for a mandibular body bilateral
comminuted and displaced fracture treated by a reconstructive
osteosynthesis plate. This 75-year-old man had local skin redness,
itching and secretions leaking within the second postoperative
week. We performed a local wound revision under local anesthesia,
and we prescribed systemic antibiotic therapy together with local
medications, and a complete wound healing was reached in 3
weeks.
All of our patients showed a steady long-term functional result,
together with a complete resolution of local complications, when
experienced, within the third month of follow-up; and all of them
completed at least 1 year of clinical-radiological control.
3.2. Surgical data
Surgery was performed within 6 days from the accident in both
groups. The median surgical procedure length was 128 min in
group A, with a mean value of 134 ± SD 5.23 (95% CI 118.25e149.75,
range 95e195) against a median value of 100 min for group B, with
a mean value of 105 ± SD 19.45 (95% CI 95.33e114.67, range
75e141), with a statistically p value of 0.002. All fractures were
treated by open reduction, but the type of osteosynthesis varied
among the two groups as explained in Materials and Methods
section.
Ten of 17 patients in group A claimed mild to moderate pain
during their first postoperative day, and none of them experienced
a grade of pain higher than 7 in accordance with the visual pain
scale; on the other hand, two patients belonging to group B claimed
local severe pain (grade 7) during the postoperative stay, and both
reported local wound complications (dehiscence and infection).
Only one patient showed extended cervical hematoma in group A,
while 5 of 18 patients (27.8%) presented diffused mandibular and
cervical hematoma in group B (p ¼ 0.1774).
The median stay at the hospital was 3 days for patients in group
A (mean 3.24 ± SD 1.52, 95% CI 2.45e4.02, range 2e7) versus a
median stay of 4 days for patients in group B (mean 3.78 ± SD 1.35,
95% CI 3.11e4.45, range 2e6) (p¼ 0.2725); in the second group, the
hospital stay was longer due to the use in two cases of local drain
tubes, which have delayed patients discharge of about 2 days;
moreover, two other patients belonging to group B reported local
severe pain, thus requiring intravenous injection of analgesic
medications for 2 days more than the other patients. Patients who
experienced diffuse cervical hematoma were kept longer to assess
its resolution.
All data are summarized in Table 3.
4. Discussion
There are no prospective, statistically validated, long-term
outcome studies concerning the treatment of fractures of the
atrophic edentulous mandible. Whether more invasively treated
fractures have a greater likelihood of complications and increased
general morbidity, and the treatment of choice, are discussed
controversially in the literature (Barber, 2001; Marciani, 2001).
Surgical techniques have improved considerably since 1976 with
Bruce and Strachan (1976), nevertheless, open reduction and in-
ternal fixation represent the universal preferred option for atrophic
mandibular fractures treatment, so far. Invasive techniques for the
treatment of the atrophic mandibular body fracture should be
considered when conservative techniques have a high likelihood of
non-union. One advantage of open techniques is the possibility of
adding autogenous bone grafts, growth factors or cell therapy with
minimally increased morbidity.
The advantage of using bone autograft is that there is no risk of
disease transmission, and that it is easily available. Although
initially it was believed to be a very cost-effective treatment, several
studies have demonstrated that the direct and indirect costs of iliac
crest bone graft harvest are substantial (St John et al., 2003).
Therefore, it is not surprising that recent advancements in regen-
erative medicine have motivated the progressively more frequent
use of engineering tissue in clinical practice to reduce possible
donor site co-morbidities and to facilitate complex surgical pro-
cedures, and afterwards, it appears to be the best choice in cases of
challenging and infrequent patients such as elderly individuals
affected by atrophic mandible fractures.
For the time being, however, iliac crest bone graft (ICBG) re-
mains the most affordable source of growth factors for bone
stimulation. The main disadvantages of ICBG relate to the limited
amount of bone that can be harvested, and the morbidity of the
procedure to the patient. Complications such as infection, seroma,
hematoma, postoperative pain, scar sensitivity, and meralgia par-
esthetica have been reported. Less commonly, major complications
such as pseudoaneurysm, arteriovenous fistula, pelvic instability,
avulsion of the anterior superior iliac spine, and hernia have also
been documented. In one study, 2.4% of patients had major com-
plications, 21.8% had minor complications, and 37.9% of patients
reported pain localized to the harvest site 6months postoperatively
(Sen andMiclau, 2007). In our study we explained how to achieve a
good final result by a less invasive technique, profiting by iliac crest
bone as stem cells donor only and using bank bone allograft instead
of autologous bone, thus obtaining a reduction of surgical proced-
ure costs and hospital stay, without affecting the final outcome.
In our series, only 3 of 14 bone grafts showed postoperative
complications; the one in group A was a 81-year-old woman
affected by diabetes and presenting with a unilateral severe dis-
placed mandibular fracture in a class III mandibular atrophy, who,
despite theminimally invasive surgical approach together the BMAC
use, experienced a wound dehiscence. The other two complications,
both non-union fractures, occurred in cases of bilateral comminuted
and displaced fractures, one patient presentingwith atrophy class III
and who received in addition the reconstructive osteosynthesis
plate. Despite the fact that the comparison of postoperative
complication events between the two analyzed groups was not
Table 3
Surgical characteristics of both study groups.
Group A Group B p Value
Surgical procedure length (minutes) median (range) 128 (95e195) 100 (75e141) 0.002
Plates and screws 2.0 (number of fractures) 30 25 0.0240
Reconstructive osteosynthesis plates with 2.3 screws e 6
BMACs use 30 e e
Postoperative pain Mild 10 8 1.000
Moderate 7 8
Severe e 2
Diffused local-cervical hematoma 1 5 0.1774
Hospital stay (days) median (range) 3 (2e7) 4 (2e6) 0.2725
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statically significant (p ¼ 0.3377), their incidence was higher in
patients treated without BMACs than in group A; this could find a
reason in the use of a wider surgical incision, implying the exposure
of almost all of the mandibular body, to allow the use of large
reconstructive osteosynthesis plates, which had been seen associ-
ated with a three-time higher incidence of local complications. In
this setting, we emphasize that the longer surgical procedure length
of group A in comparison to group B could be justified by the need to
flatten a learning curve where a new minimally invasive approach
requires the use of small skin incisions (shorter than 4.5 cm), even in
case of multiple, comminuted and displaced fractures, togetherwith
the use of plate and screws 2.0 only, and the final addition of
regenerative tissue. Nevertheless, the shorter hospital stay recorded
in the BMACs group than in group B, together with the lower
complication incidence, show the presence of a concrete healing
process enhanced by the new surgical protocol.
In our opinion, adding BM-derived progenitor cells can enhance
the local concentration of osteoprogenitor cells which are capable
of differentiating into osteoblasts and migrating to the bone graft,
where they settle, proliferate, differentiate into osteoblasts, and
form new bone tissue (Caplan and Bruder, 2001). Yuan et al. (2007)
showed in a canine model that critical-sized segmental defects of
the canine mandible can be repaired by osteogenically induced
BMSCs with a biodegradable b-TCP scaffold. Moreover, the addition
of platelet-rich plasma (PRP), which includes various growth fac-
tors (Marx et al., 1988) and offers osteoinductive properties (Kanno
et al., 2005), contributes to cellular proliferation, matrix formation,
collagen synthesis, osteoid production, and other processes that
accelerate tissue regeneration. In terms of using these autologous
materials, tissue engineering for bone regeneration has been
shown to be an attractive alternative to autogenous or synthetic
bone substitutes (Ito et al., 2006; Yamada et al., 2004; Buser et al.,
1990). It has the additional advantage of using the host as a donor
source, which avoids bone graft donor site morbidity. Animal
studies have yielded variable results (Gandhi et al., 2006; Gerard
et al., 2006; Sarkar et al., 2006). Unfortunately, clinical studies
have not seen the same success with the use of PRP as has been
seen with other osteoinductive products such as BMPs (Carreon
et al., 2005). This lack of success may be due to the relatively low
concentration of growth factors that can be extracted in this
mannerdonly about five times the concentration of plasma
(Gerard et al., 2006) compared with the 10-fold (Carreon et al.,
2005) increase in synthetic BMPs (Westerhuis et al., 2005).
Several key questions related to the techniques of edentulous
mandible fracture repair and the uniqueness of the surgical envi-
ronment remain unanswered (Marciani, 2001). In fact, although it
is impossible to ascertain from the recent literature how patients
who received more or less invasive procedures would have fared if
left untreated or treated to a dysfunctional endpoint because of lack
of prospective and large cases studies, from our preliminary results
we can advocate a surgical approach that encourages the following:
1) to use aminimally invasive surgical approach in patients over 65
years with co-morbidities who are affected by mandibular at-
rophy class II or III, even in the case of comminuted and dis-
placed fractures, by avoiding the use of large reconstructive
osteosynthesis plates, in order to reduce hospital stay and
postoperative complications;
2) to always consider co-morbidities to prevent possible wound
healing delay and to better address the surgical protocol; in fact,
large skin incisions and wide exposure of the mandible should
be prevented mainly in patients affected by diabetes and
vascular systemic disease;
3) bone bank allograft is strongly recommended in cases of
comminuted and displaced fractures for classes II and III of
mandibular atrophy, instead of harvesting iliac crest bone graft,
which could make surgical operation time much longer than
usual, and which is linked to a higher donor site morbidity in
elderly patients;
4) a minimally invasive approach should always consist in per-
forming extra-oral open access, with a skin incision length be-
tween 3 and 4.5 cm, using osteosynthesis plates and 2.0 screws;
5) injection of BMACs sub-periosteally, after osteosynthesis plates
have been fixed;
6) to reduce surgical operation length, TEB and PRP could be har-
vested and prepared simultaneously at the beginning of the
operation, by a second surgeon.
5. Conclusion
Here, we have demonstrated consistent results from the first-in-
human study for atrophic mandibular bone fracture regeneration
using BMACs in combination with a less invasive surgical approach,
yielding good immediate results and ensuring functional long-term
outcomes in patients with mandibular fractures in atrophy classes II
and III. Despite the fact that an early learning curve could affect
surgical procedure length (p ¼ 0.002), technical details such as a
faster recoverywith an overall hospital stay 1 day shorter than usual
(p ¼ 0.2725) and a lower incidence of postoperative complications,
are worth mentioning and are considered in our final results anal-
ysis. Because this study aimed to assess the safety and response to
BMAC usewith a small but, in our opinion, significant patients group
because of the uncommon pathology, we can affirm that this tech-
nique provides an easily renewable and reliable source of osteogenic
stem cells with numerous advantages when compared with stan-
dard open-grafting techniques and related outcomes.
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